Literature DB >> 21890509

Transient lower esophageal sphincter relaxation pharmacokinetic-pharmacodynamic modeling: count model and repeated time-to-event model.

Elodie L Plan1, Guangli Ma, Mats Någård, Jörgen Jensen, Mats O Karlsson.   

Abstract

Transient lower esophageal sphincter relaxation (TLESR) is the major mechanism for gastroesophageal reflux. Characterizations of candidate compounds for reduction of TLESRs are traditionally done through summary exposure and response measures and would benefit from model-based analyses of exposure-TLESR events relationships. Pharmacokinetic (PK)-pharmacodynamic (PD) modeling approaches treating TLESRs either as count data or repeated time-to-event (RTTE) data were developed and compared in terms of their ability to characterize system and drug characteristics. Vehicle data comprising 294 TLESR events were collected from nine dogs. Compound [(R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone mesylate (WIN55212-2)] data containing 66 TLESR events, as well as plasma concentrations, were obtained from four dogs. Each experiment lasted for 45 min and was initiated with a meal. Counts in equispaced 5- and 1-min intervals were modeled based on a Poisson probability distribution model. TLESR events were analyzed with the RTTE model. The PK was connected to the PD with a one-compartment model. Vehicle data were described by a baseline and a surge function; the surge peak was determined to be approximately 9.69 min by all approaches, and its width in time at half-maximal intensity was 5 min (1-min count and RTTE) or 10 min (5-min count). TLESR inhibition by WIN55212-2 was described by an I(max) model, with an IC(50) of on average 2.39 nmol · l(-1). Modeling approaches using count or RTTE data linked to a dynamic PK-PD representation of exposure are superior to using summary PK and PD measures and are associated with a higher power for detecting a statistically significant drug effect.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21890509     DOI: 10.1124/jpet.111.181636

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  Kernel-Based Visual Hazard Comparison (kbVHC): a Simulation-Free Diagnostic for Parametric Repeated Time-to-Event Models.

Authors:  Sebastiaan C Goulooze; Pyry A J Välitalo; Catherijne A J Knibbe; Elke H J Krekels
Journal:  AAPS J       Date:  2017-11-27       Impact factor: 4.009

2.  N-acetyltransferase genotypes and the pharmacokinetics and tolerability of para-aminosalicylic acid in patients with drug-resistant pulmonary tuberculosis.

Authors:  Sherwin K B Sy; Lizanne de Kock; Andreas H Diacon; Cedric J Werely; Huiming Xia; Bernd Rosenkranz; Lize van der Merwe; Peter R Donald
Journal:  Antimicrob Agents Chemother       Date:  2015-05-11       Impact factor: 5.191

3.  Evaluation of estimation methods and power of tests of discrete covariates in repeated time-to-event parametric models: application to Gaucher patients treated by imiglucerase.

Authors:  Marie Vigan; Jérôme Stirnemann; France Mentré
Journal:  AAPS J       Date:  2014-02-26       Impact factor: 4.009

4.  Modeling and simulation of count data.

Authors:  E L Plan
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-08-13

Review 5.  Review: The Role of Cannabinoids on Esophageal Function-What We Know Thus Far.

Authors:  Jonathan Gotfried; Rahul Kataria; Ron Schey
Journal:  Cannabis Cannabinoid Res       Date:  2017-10-01

6.  A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A.

Authors:  Koichiro Yoneyama; Christophe Schmitt; Naoki Kotani; Gallia G Levy; Ryu Kasai; Satofumi Iida; Midori Shima; Takehiko Kawanishi
Journal:  Clin Pharmacokinet       Date:  2018-09       Impact factor: 6.447

7.  Population repeated time-to-event analysis of exacerbations in asthma patients: A novel approach for predicting asthma exacerbations based on biomarkers, spirometry, and diaries/questionnaires.

Authors:  Robin J Svensson; Jakob Ribbing; Naoki Kotani; Michael Dolton; Shweta Vadhavkar; Dorothy Cheung; Tracy Staton; David F Choy; Wendy Putnam; Jin Jin; Nageshwar Budha; Mats O Karlsson; Angelica Quartino; Rui Zhu
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-08-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.